Log In
Print
BCIQ
Print
Print this Print this
 

Lymphoseek, tilmanocept

Also known as: 99mTc-DTPA (formerly Mannosyl-Dextran)

  Manage Alerts
Collapse Summary General Information
Company Navidea Biopharmaceuticals Inc.
DescriptionRadioisotope technetium-99m that binds to mannose binding receptor (MBR; CD206) proteins on the surface of immune cells
Molecular Target Mannose binding receptor (MBR) (CD206)
Mechanism of ActionDiagnostic; Imaging agent
Therapeutic ModalityDiagnostics
Latest Stage of DevelopmentMarketed
Standard IndicationCancer, Diagnostic
Indication DetailsDetect lymph nodes for biopsy around tumors; Detect sentinel lymph nodes in patients with head and neck cancer; Detect sentinel lymph nodes in patients with squamous cell carcinoma of the head and neck (SCCHN); Identification of the sentinel lymph node (SLN); Identify excised lymph nodes in patients with known melanoma and breast cancer; Identify lymph nodes draining from a primary tumor; Identify sentinel lymph nodes in melanoma patients; Intraoperative lymph node mapping in patients with colorectal cancer; Intraoperative lymph node mapping in patients with melanoma or breast cancer
Regulatory Designation

U.S. - Fast Track (Detect sentinel lymph nodes in patients with head and neck cancer);
U.S. - Orphan Drug (Detect sentinel lymph nodes in patients with head and neck cancer);
U.S. - Priority Review (Detect sentinel lymph nodes in patients with head and neck cancer)

Partner

Cardinal Health Inc.; Hainan Sinotau Pharmaceutical Co. Ltd


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today